Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews published research on nattokinase supplementation. It is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before beginning any supplement regimen or making changes to cardiovascular health management — particularly if you take anticoagulant or antiplatelet medication.

What you’re deciding when you look at nattokinase capsules

Nattokinase appears on supplement shelves labeled as a “natural fibrinolytic enzyme” or “cardiovascular support.” The claims reference Japan, fermented soybeans, and something about dissolving clots. You want to know what the underlying research actually shows — not the marketing version — and whether the evidence is strong enough to justify buying a bottle.

The honest position: nattokinase has one of the better-defined fibrinolytic mechanisms in the supplement category, supported by preclinical work and a modest human biomarker evidence base. The gap between “fibrin dissolution in laboratory conditions” and “meaningful cardiovascular protection in humans” is wider than most product pages acknowledge. Here is what the research record actually shows, and what it does not.

How nattokinase interacts with fibrin

Nattokinase is a serine protease — an enzyme that cleaves protein chains — produced during the fermentation of soybeans by Bacillus subtilis var. natto. It was characterized in 1987 by Hiroyuki Sumi’s research group, who observed that a natto extract placed on a fibrin clot in laboratory conditions dissolved the clot over several hours — faster than most comparable substances tested at the time. That in vitro observation set the research agenda.

The proposed fibrinolytic mechanisms operate on two levels:

• Direct fibrin cleavage: nattokinase cleaves fibrin strands in a manner structurally similar to plasmin, the body’s native fibrin-dissolving enzyme
• Endogenous fibrinolysis upregulation: at the biomarker level, nattokinase appears to stimulate tissue plasminogen activator (tPA) and reduce plasminogen activator inhibitor-1 (PAI-1), the two regulatory proteins that together govern the rate of the body’s own clot-clearing system

Both pathways have been demonstrated in cell and animal models. The pharmacological question is whether an oral dose survives gastrointestinal transit as enzymatically active protein. Nattokinase is a protein, and digestive proteases degrade dietary proteins extensively. Some pharmacokinetic studies suggest partial absorption of enzymatically active nattokinase into circulation; others have not replicated this clearly. The debate around bioavailability is part of why enteric-coated formulations became a product category — the coating is designed to delay capsule dissolution until the enzyme is past the stomach’s acidic environment.

Suzuki 2003 and the early experimental evidence

One of the foundational preclinical studies for nattokinase’s cardiovascular relevance is the work by Suzuki and colleagues, published in 2003 (Nutrition, 19(3):261–4), which used a rat femoral artery injury model to examine the effects of fermented soybean supplementation on thrombus formation and vascular remodeling.

In that animal model, dietary supplementation with fermented soybeans was associated with modified thrombus lysis dynamics and suppressed intimal thickening in the treated group compared to untreated controls. The finding was significant for establishing proof-of-concept in a living biological system rather than a test tube: the compound appeared to influence clotting dynamics in an arterial injury context, not just in isolated fibrin.

The limitations of animal model data are real and worth naming explicitly. A rat arterial injury model establishes mechanistic plausibility; it does not establish that nattokinase supplementation in healthy humans modifies clot risk or cardiovascular outcomes. Rodent coagulation physiology and dose scaling differ meaningfully from human applications. Suzuki 2003 is part of the rationale for conducting human trials, not a clinical outcome finding.

The Kim 2008 RCT: fibrinolysis markers in a controlled human trial

The most rigorously designed human trial for nattokinase to date is Kim et al. 2008 (Hypertension Research, 31(8):1583–1588; PubMed 18971533). The trial enrolled 86 adults with pre-hypertension or stage 1 hypertension, randomized them to 2,000 FU nattokinase per day or placebo for 8 weeks, and measured cardiovascular biomarkers as secondary outcomes alongside blood pressure as the primary endpoint.

The blood pressure findings — a net systolic reduction of approximately 3 mmHg versus placebo — are covered separately in Nattokinase and Blood Pressure: What the RCTs Actually Show. The fibrinolysis biomarker data from the same trial is the relevant finding here.

The supplemented group in Kim 2008 showed changes consistent with increased fibrinolytic activity: PAI-1 levels were reduced and tPA activity was elevated relative to the placebo group. These changes were statistically significant. The direction of effect matches the proposed mechanism — lower PAI-1 means less inhibition of the body’s clot-clearing system; higher tPA means more fibrinolytic enzyme active in circulation.

What the biomarker data does not establish: a connection between these marker changes and reduced thromboembolic events. Elevated tPA and reduced PAI-1 in an 86-person, 8-week trial in adults with elevated blood pressure is evidence of a mechanism — not evidence of reduced stroke or MI risk. No published randomized trial has used an actual clotting event as a primary endpoint for nattokinase. The fibrinolysis markers are a plausible intermediate, not a validated clinical endpoint.

The 2018 meta-analysis of multiple nattokinase trials noted broadly consistent fibrinolysis marker changes across studies at the 2,000–4,000 FU/day dose range, while also observing significant heterogeneity in trial populations and duration. The marker signal has been replicated across multiple independent studies; the clinical translation remains to be established.

NSK-SD standardization: why Fibrinolytic Units matter

Consumer nattokinase products are standardized in Fibrinolytic Units (FU), a measure of enzymatic activity against a standardized fibrin substrate under controlled laboratory conditions. This standardization matters because the milligram content of a capsule tells you almost nothing about enzymatic potency — different extraction and production methods yield substantially different FU per milligram of raw material.

NSK-SD is a standardized nattokinase extract developed by Japan Bio Science Laboratory, used as the test material in a number of published human trials and carried by a subset of mainstream supplement brands including Doctor’s Best. NSK-SD products carry FU documentation from the manufacturer with FU assay data available on request, which is the practical meaning of using this form: there is a traceable manufacturing standard behind the label claim.

For a retail supplement buyer, NSK-SD specification is one of the stronger quality signals available. It distinguishes a product with documented FU activity from one where the only quantity stated on the label is milligrams — which, without an FU count, provides no usable potency information.

Study doses in the published human trial record cluster at 2,000–4,000 FU per day. Standard capsules are typically 100–200 mg of nattokinase standardized to 2,000 FU per capsule. One capsule per day at 2,000 FU is the dose tier most consistently associated with the biomarker changes in the published literature. No trial data supports benefit above 4,000 FU/day, and no clear dose-response advantage between 2,000 and 4,000 FU has emerged from the blood pressure or fibrinolysis marker trials.

One additional product consideration: nattokinase supplements do not contain meaningful vitamin K2. If MK-7 is also part of the goal — which it may be for people interested in natto’s broader cardiovascular associations — a separate MK-7 supplement or the food form is needed. Some combination products exist; read labels to confirm what is actually present.

Drug interactions: the section most buyers underweight

Nattokinase’s fibrinolytic activity is precisely the property that creates clinically meaningful drug interaction risk. If you take any medication affecting clotting, this section is more important than the evidence summary above.

Warfarin (Coumadin): case reports in the clinical literature document INR elevation when nattokinase is added to ongoing warfarin therapy. Multiple clinical reference databases classify this combination as a contraindication — not a caution, but a contraindication. Physician consultation is required before considering this supplement if you take warfarin.

Direct oral anticoagulants (rivaroxaban, apixaban, dabigatran, edoxaban): no direct interaction trial data exists for DOACs plus nattokinase, but the mechanistic basis for concern parallels the warfarin case. Given the narrow therapeutic windows of these medications and their widespread use, adding nattokinase without physician awareness is not appropriate.

Aspirin and antiplatelet agents (clopidogrel, ticagrelor, prasugrel): additive fibrinolytic effects are mechanistically plausible. The combination is consistently flagged in clinical references; trial data on combined use in humans is limited, but the theoretical basis for bleeding risk is real.

NSAIDs taken regularly: lower-tier concern relative to anticoagulants, but mild antiplatelet overlap is present and worth noting if NSAID use is regular or high-dose.

Upcoming surgery or procedures: standard clinical guidance is to stop fibrinolytic supplements two to four weeks before any planned surgery or invasive procedure due to potential effects on intraoperative and post-procedural hemostasis.

Where to find NSK-SD nattokinase

For supplement buyers in the US looking for 2,000 FU standardized nattokinase with NSK-SD documentation:

Amazon US — NSK-SD nattokinase capsules: Search “nattokinase NSK-SD capsules.” Doctor’s Best Nattokinase NSK-SD is the most widely stocked option at this standard in the US market. Typical retail pricing in 2026 runs $15–28 for a 90-day supply at 2,000 FU/day. Filter for products with a stated FU count on the label — avoid products listing milligrams only without FU documentation.

Amazon US — nattokinase capsules fibrinolytic units: If NSK-SD is out of stock, this search surfaces comparable standardized alternatives. The filter criterion is the same: FU stated on the label, not milligrams alone, and an enteric coating if bioavailability is a priority for you.

If you want the food form rather than a supplement — which provides nattokinase alongside MK-7, spermidine, live Bacillus subtilis bacteria, and prebiotic soy oligosaccharides that the capsule form omits — Natto’s Spore-Forming Bacteria, MK-7 Biosynthesis, and Gut Microbiome Research covers the full fermentation compound profile and sourcing options outside Japan in detail.

Who should not take nattokinase

The following groups should not add nattokinase without physician review first:

• Anyone taking warfarin, acenocoumarol, or other vitamin K antagonist anticoagulants (may be contraindicated)
• Anyone taking a direct oral anticoagulant (rivaroxaban, apixaban, dabigatran)
• Anyone with a history of bleeding disorders, hemorrhagic stroke, or active bleeding risk
• Anyone scheduled for surgery or an invasive procedure within four weeks
• Pregnant or breastfeeding women (no published safety data exists for this population)

For everyone else: nattokinase has a biologically plausible fibrinolytic mechanism, a consistent biomarker signal in human trials, and one methodologically solid small-sample RCT. It occupies a real — if limited — position in the supplement evidence hierarchy. A 90-day trial at 2,000 FU/day using an NSK-SD standardized product, with physician awareness, is a calibrated approach for an adult without the above contraindications who is specifically interested in the fibrinolytic mechanism.

It is not a substitute for anticoagulant therapy. It is not a clot-prevention drug. No published trial has demonstrated reduction in thromboembolic events. That calibration matters both legally and practically — and it is what an honest evidence summary requires.

---

Related: Nattokinase and Blood Pressure: What the RCTs Actually Show | Natto’s Spore-Forming Bacteria: Bacillus subtilis, MK-7, and Gut Microbiome Research | NMN vs NR: what human trials actually compare on dose, cost, and safety